Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$12.21 USD
+0.39 (3.30%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $12.30 +0.09 (0.74%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PHAT 12.21 +0.39(3.30%)
Will PHAT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
MannKind (MNKD) Reports Break-Even Earnings for Q2
Other News for PHAT
NR7 appears for PHAT after 3.3% move
Is PHAT signaling a buying opportunity? 20 Day Moving Average Support shows up after declining 3.82%
Is PHAT primed for upward momentum? Crossed Above 20 Day Moving Average shows up after advancing 4.42%
PHAT forms Pocket Pivot on September 30
12 Health Care Stocks Moving In Wednesday's After-Market Session